Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,137.01 -23.94 (-2.06%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$1,135.50 -1.51 (-0.13%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $1,138.78, reflecting strong market performance and investor confidence.
  • Eli Lilly and Co reported impressive quarterly earnings, with earnings per share (EPS) significantly exceeding analyst expectations, indicating robust financial health.
  • The company has a high return on equity of over 105%, showcasing its efficiency in generating profits from shareholders' equity.

Cons of Eli Lilly and Company

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 41.27, which may suggest that it is overvalued compared to its earnings.
  • Despite strong revenue growth, the company faces increasing competition in the pharmaceutical sector, which could impact future profitability.
  • The beta of 0.53 indicates lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.07 trillion
P/E Ratio
40.39
Consensus Rating
Moderate Buy
Consensus Price Target
$1,227.74 (+8.0% Upside)
Volume
2.43 million shares
Average Volume
3.10 million shares
Today's Range
$1,132.81
$1,169.99
50-Day Range
$851.65
$1,161.75
52-Week Range
$623.78
$1,182.73
Dividend Yield
0.61%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$240.57 +2.24 (+0.94%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$240.50 -0.06 (-0.03%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson has recently secured extended NICE approval for its product Darzalex, which is a significant development in the oncology sector, potentially leading to increased sales and market share.
  • The current stock price is around $275, reflecting positive sentiment and expectations for continued growth driven by strong performance in oncology and MedTech sectors.
  • Analysts have a consensus rating of "Moderate Buy" for Johnson & Johnson, indicating confidence in the company's future performance, with many analysts setting target prices above the current stock price.

Cons of Johnson & Johnson

  • Johnson & Johnson faces ongoing patent and legal headwinds, which could impact its profitability and market position in the long term.
  • Some recent coverage has highlighted that while the healthcare sector is viewed as a defensive trade, it may not provide specific catalysts for Johnson & Johnson's stock performance.
  • Despite positive analyst ratings, there is a risk that the stock may not reach the higher target prices set by analysts, leading to potential disappointment for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$579.83 billion
P/E Ratio
27.81
Consensus Rating
Moderate Buy
Consensus Price Target
$253.04 (+5.2% Upside)
Volume
6.46 million shares
Average Volume
7.25 million shares
Today's Range
$237.52
$240.91
50-Day Range
$221.17
$242.93
52-Week Range
$149.04
$251.71
Dividend Yield
2.23%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$227.54 +2.77 (+1.23%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$226.28 -1.27 (-0.56%)
As of 06/12/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $227, reflecting a stable market position and potential for growth.
  • AbbVie has shown strong institutional interest, with significant increases in holdings from various hedge funds, indicating confidence in the company's future performance.
  • The company reported earnings per share (EPS) of $2.65, surpassing analysts' expectations, which suggests robust financial health and operational efficiency.

Cons of AbbVie

  • AbbVie has a negative return on equity of 576.45%, which may raise concerns about the company's efficiency in generating profits from its equity investments.
  • The price-to-earnings (P/E) ratio is relatively high at 112.16, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite recent growth, the company's net margin of 5.79% indicates that profitability may be under pressure, which could affect future earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$402.35 billion
P/E Ratio
112.09
Consensus Rating
Moderate Buy
Consensus Price Target
$253.43 (+11.4% Upside)
Volume
4.08 million shares
Average Volume
5.01 million shares
Today's Range
$224.32
$228.40
50-Day Range
$197.24
$227.68
52-Week Range
$181.73
$244.81
Dividend Yield
3.04%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$408.34 +2.79 (+0.69%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$408.45 +0.11 (+0.03%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Market Capitalization
$371.00 billion
P/E Ratio
30.84
Consensus Rating
Moderate Buy
Consensus Price Target
$407.17 (-0.3% Downside)
Volume
7.26 million shares
Average Volume
6.62 million shares
Today's Range
$404.81
$409.89
50-Day Range
$277.30
$412.57
52-Week Range
$234.60
$415.98
Dividend Yield
2.16%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$119.05 -1.71 (-1.41%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$119.24 +0.19 (+0.16%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $121, reflecting strong market interest and confidence in the company's future performance.
  • Merck has a robust market capitalization of approximately $298.96 billion, indicating its significant presence and stability in the pharmaceutical industry.
  • Recent investments by large institutional investors, such as Norges Bank and DLD Asset Management, suggest a positive outlook on Merck's growth potential.

Cons of Merck & Co., Inc.

  • Merck's price-to-earnings ratio of 34.10 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • The company has a debt-to-equity ratio of 1.02, suggesting that it has a significant amount of debt relative to its equity, which could pose risks in times of economic downturn.
  • Despite recent positive developments, the pharmaceutical industry is highly competitive, and Merck faces ongoing challenges from generic drug manufacturers and other competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$294.03 billion
P/E Ratio
21.76
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+7.7% Upside)
Volume
10.93 million shares
Average Volume
10.21 million shares
Today's Range
$118.83
$121.90
50-Day Range
$109.33
$123.25
52-Week Range
$76.66
$125.14
Dividend Yield
2.86%
Novartis stock logo

6. Novartis NYSE:NVS

$153.03 -0.89 (-0.58%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$152.63 -0.40 (-0.26%)
As of 06/12/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $145.98, which is near its 50-day moving average, indicating potential stability in the short term.
  • Novartis AG has a strong market capitalization of approximately $278.56 billion, reflecting its significant presence and stability in the pharmaceutical industry.
  • The company reported a net margin of nearly 25%, showcasing its ability to convert revenue into profit effectively.

Cons of Novartis

  • The company recently missed earnings expectations, reporting an EPS of $1.99 compared to the consensus estimate of $2.11, which may raise concerns about its growth trajectory.
  • Novartis AG's quarterly revenue showed a slight decline of 0.9% year-over-year, suggesting potential challenges in maintaining sales growth.
  • The stock has a relatively high P/E ratio of 20.91, which may indicate that it is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$292.08 billion
P/E Ratio
21.92
Consensus Rating
Hold
Consensus Price Target
$141.20 (-7.7% Downside)
Volume
1.18 million shares
Average Volume
1.60 million shares
Today's Range
$152.85
$154.22
50-Day Range
$142.99
$155.11
52-Week Range
$112.34
$170.46
Dividend Yield
2.01%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$43.90 -0.06 (-0.13%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$44.02 +0.12 (+0.28%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent upgrades from investment analysts, including a shift from a "hold" to a "buy" rating, indicate growing confidence in the company's future performance.
  • The current stock price is around $44, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Analysts have boosted earnings per share (EPS) estimates for FY2027, suggesting that the company is expected to generate higher profits, which can lead to increased shareholder value.

Cons of Novo Nordisk A/S

  • Some analysts have downgraded the stock to a "hold" rating, suggesting that there may be concerns about its short-term performance.
  • The stock has experienced fluctuations, with a 12-month high of $81.44 and a low of $35.12, indicating potential volatility that could deter risk-averse investors.
  • Recent reports show that several brokerages have lowered their price targets for the stock, which may reflect a cautious outlook on its future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$195.92 billion
P/E Ratio
10.31
Consensus Rating
Hold
Consensus Price Target
$65.56 (+49.3% Upside)
Volume
14.79 million shares
Average Volume
12.64 million shares
Today's Range
$43.72
$44.60
50-Day Range
$36.66
$47.13
52-Week Range
$35.12
$81.44
Dividend Yield
3.98%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$355.20 +1.14 (+0.32%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$353.42 -1.78 (-0.50%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has received a cautious Buy rating from analysts, highlighting improved fundamentals and a diversified pipeline, which suggests potential for future growth.
  • The current stock price is around $337.73, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high.
  • Recent quarterly earnings exceeded analysts' expectations, with a reported EPS of $5.15, indicating strong financial performance and effective management.

Cons of Amgen

  • Amgen Inc. has underperformed compared to some peers, which may indicate challenges in maintaining competitive advantage in the biotechnology market.
  • Recent market commentary suggests that the stock has experienced a significant drop, reflecting short-term profit-taking and weaker momentum, which could deter new investors.
  • The company's high debt-to-equity ratio of 5.65 raises concerns about financial leverage and the potential risks associated with high levels of debt.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$191.70 billion
P/E Ratio
24.72
Consensus Rating
Hold
Consensus Price Target
$354.12 (-0.3% Downside)
Volume
2.73 million shares
Average Volume
2.51 million shares
Today's Range
$351.96
$358.17
50-Day Range
$324.39
$355.60
52-Week Range
$267.83
$391.29
Dividend Yield
2.84%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$468.80 -6.86 (-1.44%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$470.00 +1.20 (+0.26%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company has shown a solid revenue growth of 6.2% year-over-year, indicating a strong demand for its products and services in the scientific instrumentation and laboratory sectors.
  • Thermo Fisher Scientific Inc. has a favorable average rating of "Moderate Buy" from analysts, suggesting positive sentiment in the market regarding its future performance.
  • The current stock price is around $613.67, which reflects a competitive valuation in the context of its growth potential and market position.

Cons of Thermo Fisher Scientific

  • Recent downgrades from analysts, including a shift from "buy" to "hold," may signal concerns about the stock's short-term performance and market conditions.
  • Some analysts have reduced their price targets, with one dropping from $670.00 to $540.00, which could indicate a more cautious outlook on the company's growth prospects.
  • Insider selling activity, such as the COO selling shares, may raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$174.42 billion
P/E Ratio
25.77
Consensus Rating
Moderate Buy
Consensus Price Target
$608.95 (+29.9% Upside)
Volume
2.39 million shares
Average Volume
2.36 million shares
Today's Range
$467.63
$481.92
50-Day Range
$438.16
$531.69
52-Week Range
$385.46
$643.99
Dividend Yield
0.40%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$125.59 -0.28 (-0.22%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$125.83 +0.24 (+0.19%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Capitalization
$155.93 billion
P/E Ratio
17.11
Consensus Rating
Moderate Buy
Consensus Price Target
$156.93 (+25.0% Upside)
Volume
5.21 million shares
Average Volume
7.67 million shares
Today's Range
$124.29
$126.51
50-Day Range
$121.48
$142.09
52-Week Range
$104.46
$157.29
Dividend Yield
2.61%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$87.89 -1.76 (-1.97%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$88.27 +0.38 (+0.43%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $92.80, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Abbott Laboratories reported a strong quarterly earnings performance, with earnings per share of $1.15, exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $158.85 billion, reflecting its significant presence and stability in the healthcare market.

Cons of Abbott Laboratories

  • The stock has a relatively high P/E ratio of 25.55, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Abbott Laboratories has a beta of 0.63, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • The company’s two-hundred day moving average is significantly higher at $109.16, indicating that the stock may be underperforming relative to its historical performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.59 billion
P/E Ratio
24.62
Consensus Rating
Moderate Buy
Consensus Price Target
$118.38 (+34.7% Upside)
Volume
13.76 million shares
Average Volume
11.39 million shares
Today's Range
$87.07
$90.29
50-Day Range
$82.58
$103.70
52-Week Range
$81.97
$139.06
Dividend Yield
2.86%
Pfizer stock logo

12. Pfizer NYSE:PFE

$26.19 +0.02 (+0.07%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$26.20 +0.02 (+0.06%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $26.56, which is near its 200-day simple moving average, indicating stability in its recent performance.
  • Pfizer Inc. reported a revenue increase of 5.4% year-over-year, showcasing its ability to grow despite market challenges.
  • The company has a strong net margin of 11.83%, reflecting efficient management and profitability, which can lead to higher returns for investors.

Cons of Pfizer

  • The company's payout ratio is 131.30%, indicating that it is paying out more in dividends than it earns, which could be unsustainable in the long run.
  • Pfizer Inc. has a relatively low quick ratio of 0.94, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
  • With a beta of 0.34, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$149.38 billion
P/E Ratio
19.99
Consensus Rating
Hold
Consensus Price Target
$28.82 (+10.1% Upside)
Volume
38.76 million shares
Average Volume
32.41 million shares
Today's Range
$26.11
$26.49
50-Day Range
$25.31
$28.37
52-Week Range
$23.11
$28.75
Dividend Yield
6.56%
Intuitive Surgical stock logo

13. Intuitive Surgical NASDAQ:ISRG

$411.06 -1.84 (-0.45%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$412.03 +0.97 (+0.24%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $493.95, reflecting a strong market position and investor confidence in the company's growth potential.
  • Intuitive Surgical, Inc. is a leader in robotic-assisted surgical systems, particularly known for its latest da Vinci surgical systems, which enhance precision and control in minimally invasive procedures.
  • Recent insider trading activity indicates confidence in the company's future, with executives selling shares under a pre-arranged trading plan, suggesting they believe in the company's long-term value.

Cons of Intuitive Surgical

  • Insider sales totaled 7,448 shares valued at over $3 million in the last quarter, which could signal a lack of confidence among insiders regarding short-term stock performance.
  • Despite strong institutional ownership, insiders only hold 0.60% of the company's stock, which may indicate a lack of alignment between management and shareholder interests.
  • Recent insider sales represent a 6.13% decrease in ownership for key executives, which could raise concerns about their commitment to the company's future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.58 billion
P/E Ratio
49.83
Consensus Rating
Moderate Buy
Consensus Price Target
$571.28 (+39.0% Upside)
Volume
1.78 million shares
Average Volume
2.31 million shares
Today's Range
$402.73
$415.76
50-Day Range
$402.30
$483.62
52-Week Range
$396.68
$603.88
Dividend Yield
N/A
CVS Health stock logo

14. CVS Health NYSE:CVS

$101.87 +1.39 (+1.39%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$101.95 +0.08 (+0.07%)
As of 06/12/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has recently received a positive forecast from UBS Group, raising its price target to $115, indicating a potential upside from the current stock price of around $95.65.
  • The company has a strong dividend yield of approximately 2.7%, providing investors with a steady income stream.
  • Recent insider trading activity shows significant sales by executives, which can indicate confidence in the company's future performance.

Cons of CVS Health

  • The company's dividend payout ratio is currently over 117%, which may raise concerns about sustainability and future dividend payments.
  • Recent insider sales have resulted in a significant decrease in their positions, which could signal a lack of confidence in the stock's short-term performance.
  • CVS Health Co. has a relatively high price-to-earnings (P/E) ratio of 42.16, indicating that the stock may be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$130.09 billion
P/E Ratio
44.88
Consensus Rating
Moderate Buy
Consensus Price Target
$100.68 (-1.2% Downside)
Volume
11.18 million shares
Average Volume
7.69 million shares
Today's Range
$100.01
$102.77
50-Day Range
$73.24
$101.87
52-Week Range
$58.50
$102.77
Dividend Yield
2.61%
Danaher stock logo

15. Danaher NYSE:DHR

$179.95 -0.84 (-0.46%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$180.33 +0.38 (+0.21%)
As of 06/12/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. recently reported earnings per share (EPS) of $2.06, exceeding expectations, which indicates strong financial performance and potential for growth.
  • The company has a solid revenue stream, with a reported revenue of $5.95 billion for the latest quarter, showing a year-over-year increase of 3.7%.
  • Danaher Co. has a favorable dividend policy, recently announcing a quarterly dividend of $0.40 per share, which translates to an annualized yield of approximately 1.0%, appealing to income-focused investors.

Cons of Danaher

  • The stock has experienced a decline of about 2.2% recently, which may indicate short-term volatility and potential risks for investors.
  • Analysts have adjusted their price targets downward, with some estimates dropping significantly, which could reflect concerns about future performance.
  • Danaher Co. has a relatively high price-to-earnings (P/E) ratio of 34.04, suggesting that the stock may be overvalued compared to its earnings, which could deter value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$127.47 billion
P/E Ratio
34.81
Consensus Rating
Moderate Buy
Consensus Price Target
$233.61 (+29.8% Upside)
Volume
3.13 million shares
Average Volume
4.04 million shares
Today's Range
$179.50
$182.64
50-Day Range
$161.95
$198.58
52-Week Range
$160.93
$242.80
Dividend Yield
0.89%
Stryker stock logo

16. Stryker NYSE:SYK

$312.14 +6.50 (+2.13%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$311.81 -0.33 (-0.11%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $293, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Stryker Co. has a strong market capitalization of approximately $112.46 billion, indicating a solid position in the industry and potential for stability.
  • Recent earnings reports show a year-over-year revenue increase of 2.6%, suggesting that the company is maintaining growth despite market challenges.

Cons of Stryker

  • The company recently reported earnings per share (EPS) of $2.60, which missed analysts' expectations, indicating potential challenges in meeting future financial targets.
  • Insider selling has been notable, with significant shares sold recently, which may raise concerns about the confidence of current management in the company's future performance.
  • Analysts have adjusted target prices downward, with Citigroup reducing their target from $420 to $385, suggesting a more cautious outlook on the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.69 billion
P/E Ratio
36.13
Consensus Rating
Moderate Buy
Consensus Price Target
$395.33 (+26.7% Upside)
Volume
3.18 million shares
Average Volume
2.70 million shares
Today's Range
$306.39
$314.27
50-Day Range
$282.85
$347.28
52-Week Range
$281.00
$404.87
Dividend Yield
1.13%
Bristol Myers Squibb stock logo

17. Bristol Myers Squibb NYSE:BMY

$57.05 +0.15 (+0.26%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$57.15 +0.10 (+0.18%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $58, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Bristol-Myers Squibb has recently received an EU label expansion for Opdivo, enhancing its market potential in treating advanced classical Hodgkin lymphoma, which could significantly boost future oncology revenue.
  • The company reported a strong quarterly earnings performance, with earnings per share surpassing analysts' expectations, indicating robust financial health and operational efficiency.

Cons of Bristol Myers Squibb

  • The company has a relatively high debt-to-equity ratio of 2.10, indicating that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Despite a recent earnings beat, the year-over-year decline in earnings per share suggests potential challenges in maintaining profitability in the face of competition and market pressures.
  • With a net margin of 15.01%, there may be concerns about the company's ability to sustain profitability, especially as it navigates regulatory and market challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$116.66 billion
P/E Ratio
16.02
Consensus Rating
Hold
Consensus Price Target
$61.31 (+7.5% Upside)
Volume
7.84 million shares
Average Volume
10.88 million shares
Today's Range
$56.77
$57.60
50-Day Range
$54.34
$60.75
52-Week Range
$42.52
$62.89
Dividend Yield
4.41%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$444.92 -0.12 (-0.03%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$444.68 -0.24 (-0.05%)
As of 06/12/2026 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated has received multiple upgrades from analysts, indicating strong confidence in its future performance.
  • The current stock price is around $555.91, which reflects a positive outlook based on recent analyst ratings.
  • Twenty-two investment analysts have rated the stock with a Buy rating, suggesting a consensus belief in the company's growth potential.

Cons of Vertex Pharmaceuticals

  • Despite positive ratings, there are still some analysts who have issued Hold ratings, suggesting caution in the stock's immediate prospects.
  • Market volatility can impact stock performance, and biotechnology stocks are often subject to rapid changes based on regulatory news and clinical trial results.
  • Some analysts have recently lowered their price targets, indicating potential concerns about future growth or market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$112.92 billion
P/E Ratio
26.39
Consensus Rating
Moderate Buy
Consensus Price Target
$555.91 (+24.9% Upside)
Volume
924,150 shares
Average Volume
1.24 million shares
Today's Range
$440.02
$447.70
50-Day Range
$423.24
$453.06
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
GSK stock logo

19. GSK NYSE:GSK

$53.04 +0.18 (+0.35%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$52.78 -0.27 (-0.51%)
As of 06/12/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $43.16, which may present a favorable entry point for investors looking to capitalize on potential growth.
  • GSK plc has shown a positive fifty-two week performance, indicating a potential upward trend in its stock value.
  • Institutional ownership is relatively high, suggesting that large investors have confidence in GSK plc's future prospects.

Cons of GSK

  • There has been a decline in the fifty-two week performance, which could signal potential challenges ahead for the company.
  • The average daily volume has decreased, suggesting reduced trading activity and possibly lower investor interest.
  • Recent data indicates a slight increase in shares shorted compared to the previous month, which may reflect growing skepticism among some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$107.41 billion
P/E Ratio
13.78
Consensus Rating
Hold
Consensus Price Target
$53.00 (-0.1% Downside)
Volume
3.81 million shares
Average Volume
3.57 million shares
Today's Range
$52.89
$53.45
50-Day Range
$49.06
$59.19
52-Week Range
$35.45
$61.69
Dividend Yield
3.42%
Sanofi stock logo

20. Sanofi NASDAQ:SNY

$44.25 +0.14 (+0.32%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$44.30 +0.05 (+0.10%)
As of 06/12/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $60, which is near its 1-year high, indicating strong market performance and investor confidence.
  • Sanofi has a solid market capitalization of approximately $108.66 billion, reflecting its stability and significant presence in the pharmaceutical industry.
  • The company recently increased its annual dividend to $2.4225, showcasing its commitment to returning value to shareholders and indicating strong cash flow.

Cons of Sanofi

  • The company has a relatively low quick ratio of 0.73, which may indicate potential liquidity issues in meeting short-term obligations.
  • Sanofi's beta of 0.45 suggests lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • Despite recent growth, the P/E ratio of 12.38 may indicate that the stock is fairly valued, leaving limited room for significant price appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$107.28 billion
P/E Ratio
9.64
Consensus Rating
Hold
Consensus Price Target
$51.00 (+15.3% Upside)
Volume
1.63 million shares
Average Volume
2.37 million shares
Today's Range
$44.02
$44.51
50-Day Range
$42.37
$48.06
52-Week Range
$42.28
$52.68
Dividend Yield
3.99%
Medtronic stock logo

21. Medtronic NYSE:MDT

$80.11 -0.22 (-0.27%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$80.22 +0.11 (+0.14%)
As of 06/12/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $82, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc has a strong institutional ownership, with over 82% of the stock held by institutional investors, indicating confidence in the company's long-term prospects.
  • The company recently reported a revenue increase of nearly 10% compared to the same quarter last year, showcasing its growth potential in the healthcare market.

Cons of Medtronic

  • Recent analyst reports have shown a range of price target reductions, with some analysts lowering their expectations for the stock, which may indicate caution in the market.
  • The company's earnings per share (EPS) has seen a slight decline compared to the previous year, which could raise concerns about its profitability moving forward.
  • Medtronic plc's dividend payout ratio is relatively high at over 79%, which may limit its ability to reinvest in growth opportunities or weather economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.97 billion
P/E Ratio
21.48
Consensus Rating
Moderate Buy
Consensus Price Target
$99.00 (+23.6% Upside)
Volume
7.69 million shares
Average Volume
11.43 million shares
Today's Range
$79.26
$80.74
50-Day Range
$73.72
$88.65
52-Week Range
$73.31
$106.33
Dividend Yield
3.54%
McKesson stock logo

22. McKesson NYSE:MCK

$783.88 -3.31 (-0.42%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$784.66 +0.78 (+0.10%)
As of 06/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $761, which reflects a strong position in the market and potential for growth.
  • McKesson Co. has a solid earnings per share forecast of 44.29 for the current fiscal year, indicating strong profitability expectations.
  • The company recently announced a quarterly dividend of $0.82 per share, translating to an annualized dividend of $3.28, which can provide a steady income stream for investors.

Cons of McKesson

  • Recent analyst downgrades have seen target prices adjusted downward, with Citigroup lowering its target from $975 to $945, which may indicate concerns about future performance.
  • Insider selling has been noted, with executives selling shares to cover tax obligations, which could signal a lack of confidence in the stock's short-term prospects.
  • The dividend payout ratio is currently at 8.53%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.25 billion
P/E Ratio
20.38
Consensus Rating
Moderate Buy
Consensus Price Target
$960.53 (+22.5% Upside)
Volume
608,836 shares
Average Volume
1.12 million shares
Today's Range
$782.47
$796.54
50-Day Range
$724.87
$885.42
52-Week Range
$637.00
$999.00
Dividend Yield
0.42%
Elevance Health stock logo

23. Elevance Health NYSE:ELV

$403.74 +4.56 (+1.14%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$401.50 -2.24 (-0.55%)
As of 06/12/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$87.75 billion
P/E Ratio
13.13
Consensus Rating
Moderate Buy
Consensus Price Target
$416.11 (+3.1% Upside)
Volume
1.55 million shares
Average Volume
1.61 million shares
Today's Range
$393.35
$404.07
50-Day Range
$300.99
$424.16
52-Week Range
$273.71
$426.98
Dividend Yield
1.70%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$387.25 +8.74 (+2.31%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$387.42 +0.16 (+0.04%)
As of 06/12/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $374, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • HCA Healthcare, Inc. reported a year-over-year revenue increase of 4.3%, indicating strong growth potential in its operations.
  • The company has a solid market capitalization of approximately $82.59 billion, reflecting its significant presence in the healthcare industry.

Cons of HCA Healthcare

  • The company has a negative return on equity of 295.93%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • HCA Healthcare, Inc. missed its earnings per share (EPS) estimate by $0.04 in its latest quarterly report, which could indicate potential challenges in meeting future financial expectations.
  • The firm has a relatively high beta of 1.12, suggesting that its stock price may be more volatile compared to the overall market, which could pose risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.89 billion
P/E Ratio
13.32
Consensus Rating
Moderate Buy
Consensus Price Target
$506.14 (+30.7% Upside)
Volume
1.81 million shares
Average Volume
1.76 million shares
Today's Range
$378.77
$389.96
50-Day Range
$360.99
$507.17
52-Week Range
$330.00
$556.52
Dividend Yield
0.81%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$297.77 +2.93 (+0.99%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$298.08 +0.31 (+0.11%)
As of 06/12/2026 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently reported strong quarterly earnings, with earnings per share (EPS) of $7.79, exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a consistent revenue growth of 4.6% compared to the same quarter last year, reflecting its ability to expand its market presence and customer base.
  • The current stock price is around $300, which may present a favorable entry point for investors looking for growth in the health services sector.

Cons of Cigna Group

  • The Cigna Group's net margin of 2.26% is relatively low, which may indicate challenges in maintaining profitability compared to competitors in the health services industry.
  • With a dividend payout ratio of 26.45%, there may be limited room for future dividend increases, which could deter income-focused investors.
  • The stock has a 12-month high of $338.89, suggesting that it may be trading near its peak, which could limit potential upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.83 billion
P/E Ratio
12.62
Consensus Rating
Moderate Buy
Consensus Price Target
$338.80 (+13.8% Upside)
Volume
1.32 million shares
Average Volume
1.47 million shares
Today's Range
$295.25
$299.27
50-Day Range
$269.01
$300.36
52-Week Range
$239.51
$338.89
Dividend Yield
2.09%
Boston Scientific stock logo

26. Boston Scientific NYSE:BSX

$46.82 -0.35 (-0.73%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$46.98 +0.16 (+0.34%)
As of 06/12/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $48.66, which may present a buying opportunity for investors looking for value in the medical device sector.
  • Boston Scientific Co. has recently reported an 11.6% increase in revenue compared to the same quarter last year, indicating strong growth potential.
  • The company has authorized a $5.00 billion share buyback program, suggesting that management believes the stock is undervalued and is committed to returning value to shareholders.

Cons of Boston Scientific

  • Several analysts have recently downgraded their target prices for the stock, reflecting a cautious outlook on its near-term performance.
  • The company has a relatively low insider ownership of 0.34%, which may indicate a lack of confidence from insiders in the company's future performance.
  • Despite revenue growth, the stock has experienced significant volatility, with a 12-month high of $109.50 and a low of $47.17, suggesting potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$69.72 billion
P/E Ratio
19.59
Consensus Rating
Moderate Buy
Consensus Price Target
$85.08 (+81.7% Upside)
Volume
16.76 million shares
Average Volume
22.00 million shares
Today's Range
$45.99
$47.80
50-Day Range
$46.83
$65.89
52-Week Range
$45.99
$109.50
Dividend Yield
N/A
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$612.14 +0.66 (+0.11%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$616.45 +4.31 (+0.70%)
As of 06/12/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company has demonstrated strong financial performance, with a recent revenue increase of 19% year-over-year, indicating robust growth potential.
  • Regeneron Pharmaceuticals, Inc. has a high net margin of nearly 30%, suggesting efficient management and profitability, which can lead to higher returns for investors.
  • The current stock price is around $720, reflecting a stable valuation in the biotechnology sector, which can be attractive for long-term investors.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced fluctuations, with a 12-month high of $821.11 and a low of $503.25, indicating potential volatility that could deter risk-averse investors.
  • Despite strong earnings, the price-to-earnings (P/E) ratio of 14.66 may suggest that the stock is overvalued compared to its earnings growth, which could limit upside potential.
  • Insider selling activity, such as the recent sale of shares by a director, may raise concerns about the company's future prospects and could negatively impact investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.72 billion
P/E Ratio
14.92
Consensus Rating
Moderate Buy
Consensus Price Target
$792.65 (+29.5% Upside)
Volume
717,680 shares
Average Volume
1.20 million shares
Today's Range
$605.01
$616.55
50-Day Range
$600.66
$775.53
52-Week Range
$503.25
$821.11
Dividend Yield
0.61%
argenex stock logo

28. argenex NASDAQ:ARGX

$893.52 -5.42 (-0.60%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$893.08 -0.43 (-0.05%)
As of 06/12/2026 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $730, indicating a strong market position and potential for growth.
  • argenx SE has a robust pipeline of therapies targeting various autoimmune diseases, including its lead product candidate, efgartigimod, which has shown promise in treating conditions like myasthenia gravis.
  • The company has established strategic partnerships with major firms such as AbbVie and Zai Lab, which can enhance its research capabilities and market reach.

Cons of argenex

  • The company has no institutional ownership, which may indicate a lack of confidence from larger investors.
  • Despite a promising pipeline, the biotechnology sector is highly volatile, and the success of drug candidates is uncertain, which can lead to significant stock price fluctuations.
  • With a relatively high number of shares shorted, negative sentiment could amplify if the company faces setbacks in its clinical trials or regulatory approvals.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.57 billion
P/E Ratio
39.78
Consensus Rating
Moderate Buy
Consensus Price Target
$1,019.50 (+14.1% Upside)
Volume
333,160 shares
Average Volume
308,696 shares
Today's Range
$891.34
$911.88
50-Day Range
$746.42
$898.94
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Cencora stock logo

29. Cencora NYSE:COR

$281.56 +0.08 (+0.03%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$281.74 +0.18 (+0.07%)
As of 06/12/2026 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $265, which may present a buying opportunity for investors looking for value.
  • Cencora, Inc. has a strong market capitalization of approximately $51.58 billion, indicating a solid position in the healthcare services sector.
  • The company has received multiple "overweight" ratings from analysts, suggesting confidence in its growth potential and performance.

Cons of Cencora

  • The company recently missed earnings per share estimates, reporting $4.75 compared to the expected $4.82, which may raise concerns about its profitability.
  • There is a relatively high debt-to-equity ratio of 3.40, indicating that the company relies significantly on debt financing, which can be risky in volatile markets.
  • Analysts have adjusted target prices downward, with some estimates dropping significantly, which may reflect changing market conditions or company performance expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.80 billion
P/E Ratio
21.59
Consensus Rating
Moderate Buy
Consensus Price Target
$374.00 (+32.8% Upside)
Volume
1.06 million shares
Average Volume
1.46 million shares
Today's Range
$279.62
$283.84
50-Day Range
$253.20
$327.52
52-Week Range
$244.82
$377.54
Dividend Yield
0.85%
Cardinal Health stock logo

30. Cardinal Health NYSE:CAH

$223.76 +2.60 (+1.17%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$223.22 -0.53 (-0.24%)
As of 06/12/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The company recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for growth.
  • Cardinal Health, Inc. has increased its quarterly dividend, reflecting a commitment to returning value to shareholders, which can be attractive for income-focused investors.
  • With a recent stock price around $241.80, the company is positioned within a favorable range for potential appreciation, especially given its positive earnings outlook.

Cons of Cardinal Health

  • The company has a negative return on equity, which may raise concerns about its efficiency in generating profits from shareholders' investments.
  • Despite revenue growth, the net margin remains low, suggesting that the company may face challenges in converting sales into actual profit.
  • Analysts have adjusted price targets downward, indicating some uncertainty about the stock's future performance and potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.43 billion
P/E Ratio
34.21
Consensus Rating
Moderate Buy
Consensus Price Target
$246.93 (+10.4% Upside)
Volume
2.20 million shares
Average Volume
2.08 million shares
Today's Range
$222.11
$224.88
50-Day Range
$182.62
$223.76
52-Week Range
$137.75
$233.60
Dividend Yield
0.91%
Takeda Pharmaceutical stock logo

31. Takeda Pharmaceutical NYSE:TAK

$15.92 +0.05 (+0.28%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$16.01 +0.10 (+0.60%)
As of 06/12/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited is launching a new transformation program aimed at enhancing growth, which could lead to increased revenue and profitability.
  • The company plans to increase its annual dividend to JPY 204 per share, indicating a commitment to returning value to shareholders.
  • Recent stock performance shows that the current stock price is around $16.61, which may present a buying opportunity for investors looking for growth potential.

Cons of Takeda Pharmaceutical

  • The company is undergoing a significant restructuring that will affect approximately 4,500 roles, which may lead to operational disruptions and impact employee morale.
  • Takeda has a relatively high price-to-earnings ratio of 42.59, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • There is uncertainty regarding growth projections beyond fiscal 2026, which may create concerns about the company's long-term strategic direction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.63 billion
P/E Ratio
9.25
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
3.97 million shares
Average Volume
3.05 million shares
Today's Range
$15.85
$16.03
50-Day Range
$15.02
$18.73
52-Week Range
$12.99
$18.90
Dividend Yield
1.58%
Edwards Lifesciences stock logo

32. Edwards Lifesciences NYSE:EW

$85.02 -0.75 (-0.87%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$84.73 -0.28 (-0.34%)
As of 06/12/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $81, which reflects a stable position within its 12-month range, indicating potential for growth.
  • Edwards Lifesciences Co. reported a significant revenue increase of 16.7% compared to the same quarter last year, showcasing strong demand for its products.
  • The company has a low debt-to-equity ratio of 0.06, suggesting a strong balance sheet and lower financial risk, which is attractive for investors seeking stability.

Cons of Edwards Lifesciences

  • The price-to-earnings (P/E) ratio is relatively high at around 45.71, which may indicate that the stock is overvalued compared to its earnings.
  • Despite recent revenue growth, the company operates in a competitive medical technology market, which could impact future sales and market share.
  • The beta of 0.87 suggests that the stock is less volatile than the market, which may limit potential high returns during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.01 billion
P/E Ratio
45.22
Consensus Rating
Moderate Buy
Consensus Price Target
$95.96 (+12.9% Upside)
Volume
4.57 million shares
Average Volume
4.91 million shares
Today's Range
$83.17
$86.51
50-Day Range
$77.11
$88.33
52-Week Range
$72.30
$89.48
Dividend Yield
N/A
Humana stock logo

33. Humana NYSE:HUM

$379.42 +10.73 (+2.91%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$380.00 +0.58 (+0.15%)
As of 06/12/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $304.95, which reflects a recent increase of 1.2%, indicating positive market sentiment.
  • Humana Inc. has received a consensus rating of "Hold" from analysts, suggesting that while there may not be strong buy signals, the stock is considered stable.
  • Recent upgrades from Zacks Research, moving from a "strong sell" to a "hold" rating, may indicate improving investor confidence.

Cons of Humana

  • Zacks Research has cut near-term earnings estimates for FY2026 and FY2027, indicating potential challenges in profitability.
  • Concerns have been raised about a projected large loss in Q4 2026, which could negatively impact investor sentiment and stock performance.
  • Despite recent upgrades, the stock has a significant number of analysts rating it as a "Hold" or "Sell," suggesting caution among market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.53 billion
P/E Ratio
40.58
Consensus Rating
Hold
Consensus Price Target
$291.35 (-23.2% Downside)
Volume
979,959 shares
Average Volume
1.17 million shares
Today's Range
$365.51
$379.50
50-Day Range
$178.05
$379.42
52-Week Range
$163.11
$379.50
Dividend Yield
0.93%
IDEXX Laboratories stock logo

34. IDEXX Laboratories NASDAQ:IDXX

$560.88 +2.97 (+0.53%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$561.42 +0.54 (+0.10%)
As of 06/12/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The company recently reported strong earnings, with an EPS of $3.47, surpassing analysts' expectations, indicating robust financial health.
  • IDEXX Laboratories, Inc. has shown a significant revenue increase of 14.3% compared to the same quarter last year, reflecting strong demand for its diagnostic products and services.
  • The current stock price is around $640, which may present a buying opportunity for investors looking for growth in the animal health and diagnostics sector.

Cons of IDEXX Laboratories

  • Several analysts have recently downgraded their price targets for the stock, indicating a potential lack of confidence in its short-term performance.
  • The stock has a relatively high P/E ratio of 40.19, which may suggest that it is overvalued compared to its earnings, posing a risk for new investors.
  • Recent ratings from investment firms have shifted towards a "hold" status, which may indicate uncertainty about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.24 billion
P/E Ratio
41.30
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+33.9% Upside)
Volume
516,570 shares
Average Volume
587,600 shares
Today's Range
$552.23
$561.74
50-Day Range
$528.68
$591.84
52-Week Range
$506.91
$769.98
Dividend Yield
N/A
Haleon stock logo

35. Haleon NYSE:HLN

$9.13 +0.10 (+1.14%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$9.03 -0.11 (-1.17%)
As of 06/12/2026 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.08, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a diverse product portfolio, including well-known brands in oral health, vitamins, and over-the-counter medications, which can help stabilize revenue streams.
  • The company has a long history, founded in 1715, which may instill confidence in its operational stability and experience in the market.

Cons of Haleon

  • The short percentage of float is relatively low, indicating that there may not be significant bearish sentiment currently, but this could change if market conditions shift.
  • Institutional ownership is at 0%, which may suggest a lack of confidence from larger investors, potentially impacting stock stability.
  • Recent data shows a month-to-month decrease in shares shorted, which could indicate a lack of momentum or interest in the stock from traders looking for short-term gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.39 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
8.10 million shares
Average Volume
8.21 million shares
Today's Range
$9.05
$9.15
50-Day Range
$8.71
$10.00
52-Week Range
$8.65
$11.28
Dividend Yield
2.77%
Becton, Dickinson and Company stock logo

36. Becton, Dickinson and Company NYSE:BDX

$146.13 -1.22 (-0.83%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$146.99 +0.86 (+0.59%)
As of 06/12/2026 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company has recently reported strong quarterly earnings, exceeding consensus estimates, which indicates robust financial health and operational efficiency.
  • Becton, Dickinson and Company has a solid market capitalization of approximately $41.70 billion, reflecting its significant presence in the medical technology sector.
  • The current stock price is around $183.64, which is supported by a consensus rating of "Hold" from analysts, suggesting stability in the stock's performance.

Cons of Becton, Dickinson and Company

  • The high dividend payout ratio of 106.33% raises concerns about the sustainability of future dividends, as it indicates that the company is paying out more in dividends than it earns.
  • Recent price target adjustments by analysts, including reductions from firms like Goldman Sachs, suggest a cautious outlook on the stock's future performance.
  • The company's P/E ratio of 38.31 is relatively high, which may indicate that the stock is overvalued compared to its earnings, potentially leading to price corrections.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.30 billion
P/E Ratio
37.00
Consensus Rating
Hold
Consensus Price Target
$182.73 (+25.0% Upside)
Volume
1.97 million shares
Average Volume
2.37 million shares
Today's Range
$144.40
$149.00
50-Day Range
$142.36
$158.63
52-Week Range
$127.59
$187.35
Dividend Yield
2.87%
Teva Pharmaceutical Industries stock logo

37. Teva Pharmaceutical Industries NYSE:TEVA

$34.58 +0.02 (+0.04%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$34.57 0.00 (0.00%)
As of 06/12/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$39.82 billion
P/E Ratio
12.28
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+20.8% Upside)
Volume
5.93 million shares
Average Volume
5.66 million shares
Today's Range
$33.88
$34.88
50-Day Range
$29.34
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$282.85 -6.54 (-2.26%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$284.00 +1.15 (+0.41%)
As of 06/12/2026 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $330, which reflects a strong market interest in the company's innovative RNA interference therapeutics.
  • Alnylam Pharmaceuticals, Inc. has a robust pipeline focused on RNAi therapeutics, targeting genetic drivers of various diseases, which positions the company well for future growth.
  • Recent insider trading activity indicates confidence in the company's future, with significant transactions executed under pre-arranged trading plans.

Cons of Alnylam Pharmaceuticals

  • Recent insider sales have resulted in a notable decrease in ownership percentages, which may raise concerns about the confidence of insiders in the company's future performance.
  • The biopharmaceutical sector is highly competitive, and Alnylam Pharmaceuticals, Inc. faces challenges from other companies developing similar RNAi therapies.
  • Market volatility can impact stock prices significantly, and recent fluctuations may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.76 billion
P/E Ratio
77.28
Consensus Rating
Moderate Buy
Consensus Price Target
$463.13 (+63.7% Upside)
Volume
1.42 million shares
Average Volume
998,834 shares
Today's Range
$281.77
$291.28
50-Day Range
$282.85
$339.41
52-Week Range
$281.77
$495.55
Dividend Yield
N/A
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$129.76 +0.21 (+0.16%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$128.90 -0.85 (-0.66%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently reported strong financial results, beating Wall Street’s expectations with adjusted earnings per share significantly higher than estimates, indicating robust operational performance.
  • The company raised its full-year profit outlook, reflecting confidence in continued demand for its lab tools and diagnostic products, which could lead to sustained revenue growth.
  • Recent upgrades from major financial institutions, including a shift from neutral to buy by Bank of America, suggest improved market sentiment and potential for stock appreciation.

Cons of Agilent Technologies

  • Despite positive earnings, the stock may face volatility due to market fluctuations and investor sentiment, which can impact short-term performance.
  • New product launches, while promising, may take time to gain traction in the market, potentially delaying revenue contributions.
  • Increased competition in the scientific instrumentation sector could pressure margins and market share, affecting long-term profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.67 billion
P/E Ratio
26.06
Consensus Rating
Moderate Buy
Consensus Price Target
$160.93 (+24.0% Upside)
Volume
2.29 million shares
Average Volume
2.64 million shares
Today's Range
$128.30
$130.42
50-Day Range
$110.43
$138.23
52-Week Range
$108.35
$160.27
Dividend Yield
0.79%
Waters stock logo

40. Waters NYSE:WAT

$355.10 -4.65 (-1.29%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$355.60 +0.50 (+0.14%)
As of 06/12/2026 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$34.91 billion
P/E Ratio
45.12
Consensus Rating
Moderate Buy
Consensus Price Target
$394.56 (+11.1% Upside)
Volume
780,943 shares
Average Volume
903,538 shares
Today's Range
$354.78
$365.00
50-Day Range
$291.73
$384.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Zoetis stock logo

41. Zoetis NYSE:ZTS

$79.51 -1.89 (-2.32%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$79.76 +0.24 (+0.31%)
As of 06/12/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $82, which may present a buying opportunity for investors looking for value in the market.
  • Zoetis Inc. has received recent approval for Lenivia, a long-acting osteoarthritis pain treatment for dogs, which could significantly enhance its companion-animal business and drive future revenue growth.
  • Analysts have a consensus rating of "Hold" on the stock, indicating a stable outlook, with several analysts maintaining positive ratings despite some price target adjustments.

Cons of Zoetis

  • Recent class-action lawsuits have been announced against Zoetis Inc., alleging investor harm related to securities-law violations, which could create legal and financial risks for the company.
  • Some analysts have lowered their price targets, reflecting a more cautious outlook on the stock's near-term performance.
  • The company has a relatively high debt-to-equity ratio, which may indicate increased financial risk and could affect its ability to invest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.36 billion
P/E Ratio
13.19
Consensus Rating
Hold
Consensus Price Target
$133.92 (+68.4% Upside)
Volume
6.56 million shares
Average Volume
6.79 million shares
Today's Range
$79.17
$82.40
50-Day Range
$74.11
$122.69
52-Week Range
$72.38
$167.38
Dividend Yield
2.66%
Alcon stock logo

42. Alcon NYSE:ALC

$66.83 +0.32 (+0.48%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$66.86 +0.03 (+0.04%)
As of 06/12/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $87.48, which reflects a stable valuation in the market.
  • Alcon Inc. has shown a month-to-month increase in shares shorted, indicating growing interest from investors, which can be a positive sign for future performance.
  • With an institutional ownership percentage of over 72%, a significant portion of shares is held by institutional investors, suggesting confidence in the company's long-term prospects.

Cons of Alcon

  • The fifty-two week performance shows a decline of about 7.53%, which may raise concerns about the company's growth trajectory.
  • There has been a recent increase in the short percentage of float, which can indicate that some investors are betting against the stock, potentially signaling negative sentiment.
  • The days to cover is around 4.2, suggesting that it may take several days to cover short positions, which can lead to increased volatility if the stock price moves against short sellers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.07 billion
P/E Ratio
40.26
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+27.4% Upside)
Volume
1.24 million shares
Average Volume
2.04 million shares
Today's Range
$66.10
$67.03
50-Day Range
$61.98
$81.35
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
Revolution Medicines stock logo

43. Revolution Medicines NASDAQ:RVMD

$153.87 +4.64 (+3.11%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$153.69 -0.18 (-0.12%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$32.71 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$123.72 (-19.6% Downside)
Volume
1.58 million shares
Average Volume
2.75 million shares
Today's Range
$149.67
$154.74
50-Day Range
$95.36
$163.68
52-Week Range
$34.00
$166.50
Dividend Yield
N/A
Centene stock logo

44. Centene NYSE:CNC

$65.18 +1.64 (+2.58%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$64.89 -0.28 (-0.44%)
As of 06/12/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $30, which may present a buying opportunity for investors looking for value.
  • Centene Co. has shown a significant increase in shares shorted month-over-month, indicating growing investor interest and potential for upward price movement.
  • With a high institutional ownership percentage, nearly 99%, it suggests that large investors have confidence in the company's future performance.

Cons of Centene

  • The stock has experienced a decline of approximately 66% over the past year, raising concerns about its long-term viability.
  • Short percentage of float is relatively low, which may indicate a lack of confidence among investors regarding a price rebound.
  • Recent month-to-month changes in shares shorted show only a modest increase, suggesting limited momentum in investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.19 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$60.24 (-7.6% Downside)
Volume
4.78 million shares
Average Volume
4.49 million shares
Today's Range
$63.27
$65.91
50-Day Range
$35.09
$66.23
52-Week Range
$25.08
$66.55
Dividend Yield
N/A
Royalty Pharma stock logo

45. Royalty Pharma NASDAQ:RPRX

$54.87 -0.42 (-0.76%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$55.62 +0.76 (+1.38%)
As of 06/12/2026 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $56, reflecting a strong performance in the market and investor confidence.
  • Royalty Pharma plc has a solid dividend yield of approximately 1.7%, providing a steady income stream for investors.
  • The company has received multiple upgrades from analysts, indicating positive sentiment and potential for future growth.

Cons of Royalty Pharma

  • The company has a relatively high P/E ratio of about 37.84, which may indicate that the stock is overvalued compared to its earnings.
  • Royalty Pharma plc's revenue for the latest quarter fell short of analyst estimates, raising concerns about its growth trajectory.
  • The payout ratio is currently at 63.95%, which may limit the company's ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.60 billion
P/E Ratio
37.33
Consensus Rating
Buy
Consensus Price Target
$53.71 (-2.1% Downside)
Volume
3.19 million shares
Average Volume
4.09 million shares
Today's Range
$54.77
$56.00
50-Day Range
$46.87
$55.87
52-Week Range
$34.08
$56.50
Dividend Yield
1.71%
Natera stock logo

46. Natera NASDAQ:NTRA

$212.07 -7.16 (-3.27%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$212.42 +0.35 (+0.17%)
As of 06/12/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$30.37 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.53 (+21.0% Upside)
Volume
811,684 shares
Average Volume
1.29 million shares
Today's Range
$208.79
$223.71
50-Day Range
$186.36
$223.37
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
IQVIA stock logo

47. IQVIA NYSE:IQV

$181.10 +0.04 (+0.02%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$181.42 +0.31 (+0.17%)
As of 06/12/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $178, which may present a buying opportunity for investors looking for value in the market.
  • IQVIA Holdings Inc. has recently reported strong quarterly earnings, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $29.79 billion, reflecting its significant presence and stability in the life sciences sector.

Cons of IQVIA

  • The stock has experienced volatility, with a recent drop of 12.5% in a single trading session, which may raise concerns about its short-term stability.
  • IQVIA Holdings Inc. has a relatively high debt-to-equity ratio, indicating that the company relies significantly on debt financing, which can pose risks in a rising interest rate environment.
  • Despite positive earnings, the company's P/E ratio is around 22.12, which may suggest that the stock is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.29 billion
P/E Ratio
22.44
Consensus Rating
Buy
Consensus Price Target
$224.13 (+23.8% Upside)
Volume
1.25 million shares
Average Volume
1.57 million shares
Today's Range
$177.98
$182.41
50-Day Range
$156.42
$187.14
52-Week Range
$153.01
$247.04
Dividend Yield
N/A
GE HealthCare Technologies stock logo

48. GE HealthCare Technologies NASDAQ:GEHC

$65.18 +0.67 (+1.04%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$65.54 +0.36 (+0.56%)
As of 06/12/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company has set its FY 2026 guidance at an earnings per share (EPS) range of 4.800-5.000, indicating strong future profitability expectations.
  • Research analysts forecast an EPS of 4.89 for the current fiscal year, suggesting that the company is on track to meet its financial targets.
  • Recent insider transactions show confidence in the company, with directors purchasing significant shares, indicating a positive outlook on the stock's future performance.

Cons of GE HealthCare Technologies

  • Despite positive forecasts, the company operates in a highly competitive market, which could impact its market share and profitability.
  • Insider ownership is relatively low at 0.36%, which may raise concerns about alignment between management and shareholder interests.
  • Market volatility can affect stock prices, and any downturn in the healthcare sector could negatively impact GE HealthCare Technologies Inc.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.65 billion
P/E Ratio
15.59
Consensus Rating
Moderate Buy
Consensus Price Target
$80.21 (+23.1% Upside)
Volume
3.17 million shares
Average Volume
4.53 million shares
Today's Range
$63.70
$65.41
50-Day Range
$59.49
$74.67
52-Week Range
$58.75
$89.77
Dividend Yield
0.21%
Biogen stock logo

49. Biogen NASDAQ:BIIB

$200.05 +0.09 (+0.05%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$200.00 -0.05 (-0.02%)
As of 06/12/2026 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. has recently made significant progress with its next-generation therapy for spinal muscular atrophy, which has received a breakthrough designation from the FDA, indicating strong potential for market success.
  • The company is advancing its product BIIB115 in post-gene therapy SMA, which adds to its portfolio in a key neurodegeneration market, suggesting multiple opportunities for growth.
  • Recent earnings reports showed that Biogen Inc. exceeded revenue expectations, indicating strong financial performance and potential for continued profitability.

Cons of Biogen

  • There are ongoing legal investigations related to fraud claims against Biogen Inc., which could create uncertainty and negatively impact investor sentiment.
  • Despite positive developments, the company faces challenges in the market, including competition and regulatory hurdles that could affect its product launches and sales.
  • Recent stock performance has shown volatility, with shares down about 6.4%, indicating potential instability that may concern investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.53 billion
P/E Ratio
21.46
Consensus Rating
Moderate Buy
Consensus Price Target
$217.26 (+8.6% Upside)
Volume
837,290 shares
Average Volume
951,477 shares
Today's Range
$199.06
$203.45
50-Day Range
$172.34
$204.53
52-Week Range
$121.05
$205.97
Dividend Yield
N/A
DexCom stock logo

50. DexCom NASDAQ:DXCM

$75.37 +0.12 (+0.16%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$75.60 +0.23 (+0.31%)
As of 06/12/2026 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $72.86, which reflects a strong market presence and potential for growth.
  • Analysts have a consensus rating of "Moderate Buy" with a target price averaging around $82.63, indicating optimism about future performance.
  • Recent upgrades from various analysts, including a "strong-buy" rating, suggest increasing confidence in the company's prospects.

Cons of DexCom

  • Insider selling activity has been noted, with executives reducing their holdings, which may signal concerns about the company's future performance.
  • Recent analyst reports have shown some price target reductions, indicating potential challenges in meeting previous expectations.
  • The stock has experienced fluctuations, with a 52-week low of $54.11, suggesting volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.08 billion
P/E Ratio
32.21
Consensus Rating
Moderate Buy
Consensus Price Target
$84.29 (+11.8% Upside)
Volume
4.77 million shares
Average Volume
6.63 million shares
Today's Range
$73.53
$76.25
50-Day Range
$57.56
$78.19
52-Week Range
$54.11
$89.98
Dividend Yield
N/A